Acquisition enhances market access capabilities in the U.S. to support life sciences clients in optimizing the value of their products and accelerating patient access to medical and technological advances
New York, DECEMBER 8th, 2021 – Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in building healthcare businesses, today announced the acquisition of Cyan Health (“Cyan”), a strategic payer marketing agency focused on guiding clients to successful market access for their products. Cyan is the fourth acquisition for Arsenal’s Value Demonstration organization, following the acquisitions of BresMed Health Solutions (“BresMed”) and Cello Health plc in 2020 and Guidemark Health in October 2021.
Arsenal has brought these companies together to create a unique combination of solutions to develop and communicate evidence of value to optimize patient access to new therapies.
U.S.-based Cyan identifies the critical challenges to access, develops the strategy needed for success, creates compelling communications for payers, and establishes how best to implement these in the field with payer customers.
The combined capabilities and experience of Cyan and BresMed will enable clients to understand and shape the value and access landscape, create an integrated value strategy early in the development of a product, generate evidence which demonstrates clear value, drive product access and adoption, and demonstrate value over time.
Jon Williams, CEO of Arsenal’s Value Demonstration business, said: “We are delighted to join forces with Cyan, which is an ideal fit that further enhances our offerings’ market access. We are building a market-leading global company that will develop new and transformative approaches to improve patient health by accelerating and optimizing access to medical advances. We look forward to working with our new colleagues and building a company that better meets the needs of life sciences companies and the patients whom we collectively serve.”
Amber Gilbert, Managing Director of Cyan, said: “We are thrilled to join this pioneering and fast-growing global organization. With our combined capabilities and complementary expertise, we are well-positioned to enable healthcare clients to effectively demonstrate and optimize patient access to important therapies and innovation. This is an exciting new chapter for Cyan, and we look forward to playing a valuable role in the future growth of the business.”